Literature DB >> 33499449

Retention of Coagulation Factors and Storage of Freeze-Dried Plasma.

Elissa J Flaumenhaft1, Terry Khat1, Susanne Marschner1.   

Abstract

INTRODUCTION: Terumo BCT is developing a system to produce a freeze-dried plasma product, Terumo's freeze-dried plasma (TFDP), that is stored in a rugged, light-weight plastic package suitable for field use, which retains a stable level of specific coagulation factors and proteins within clinical range, when stored for up to 2 years at room temperature and 4°C.
MATERIALS AND METHODS: Plasma frozen within 24 hours of phlebotomy (PF24) were thawed, sampled, and individually lyophilized to produce a corresponding TFDP unit. Fresh frozen plasma (FFP) units were thawed, sampled, pooled in groups of 10 units (also sampled) and lyophilized to produce 2 lots of TFDP. Each TFDP unit was reconstituted with water for injection (WFI) and tested for pH, prothrombin time, activated partial thromboplastin time, factors V and VIII, fibrinogen, protein C, and protein S. Results were compared with PF24/FFP. Additional FFP units were thawed, sampled, pooled, divided to generate 2 TFDP units for each time point (1, 2, 3, 6, 12, 18, and 24 months, one each stored at 4°C and 25°C) and lyophilized. Postlyophilization, TFDP units were stored at 4°C or 25°C, reconstituted with WFI, and tested for the factors listed above. Residual moisture content of the lyophilized plasma was also tested.
RESULTS: Coagulation factor activity of TFDP was ±20% of PF24/FFP. Pooling standardized variation in TFDP coagulation factor activities, which were within clinical ranges postlyophilization. The pH of TFDP and PF24/FFP were within required range. Residual moisture content of TFDP was <2%.
CONCLUSIONS: The TFDP process had no negative impact on coagulation factor activity. Input plasma and anticoagulant type did not affect TFDP quality. Pooling FFP normalized factor variability in TFDP and did not negatively impact product quality. The TFDP is stable for up to 24 months at room and refrigerated temperatures. Terumo's freeze-dried plasma is comparable to PF24/FFP. It does not require complex logistics or time-consuming thawing. Terumo's freeze-dried plasma may be suitable for rapid treatment of coagulopathies with logistical advantages over PF24/FFP. © The Association of Military Surgeons of the United States 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33499449     DOI: 10.1093/milmed/usaa347

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

Review 1.  Novel blood derived hemostatic agents for bleeding therapy and prophylaxis.

Authors:  Shailaja Hegde; Yi Zheng; Jose A Cancelas
Journal:  Curr Opin Hematol       Date:  2022-08-03       Impact factor: 3.218

2.  Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasma.

Authors:  Jose A Cancelas; Shawnagay Nestheide; Neeta Rugg; Anna Eckerman; Victor W Macdonald; Matthew L Charles; Luke Markstrom; Andrew J Atkinson; Melissa R King; Michele Snyder; David Burgess; James Murto; Manoj K Valiyaveettil; Joan C Pehta; Stephen A Penegor
Journal:  Transfusion       Date:  2021-12-24       Impact factor: 3.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.